These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 791234)

  • 81. Intranasal Scopolamine for Motion Sickness.
    Stankovic AS; Alvarenga DL; Coleman Daniels VR; Simmons RG; Buckey JC; Putcha L
    Aerosp Med Hum Perform; 2019 Nov; 90(11):917-924. PubMed ID: 31666152
    [No Abstract]   [Full Text] [Related]  

  • 82. Motion sickness in cats: a symptom rating scale used in laboratory and flight tests.
    Suri KB; Crampton GH; Daunton NG
    Aviat Space Environ Med; 1979 Jun; 50(6):614-8. PubMed ID: 475712
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy].
    Becker G; Goossens H; Seemann K; Souchon F; Weitz T
    Dtsch Med Wochenschr; 1984 Dec; 109(49):1881-5. PubMed ID: 6499689
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [A new approach to the search for vestibuloprotectors].
    Yasnetsov VV; Karsanova SK; Yasnetsov VV
    Aviakosm Ekolog Med; 2015; 49(1):5-12. PubMed ID: 25958460
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Influence of transdermal scopolamine on motion sickness during 7 days' exposure to heavy seas.
    van Marion WF; Bongaerts MC; Christiaanse JC; Hofkamp HG; van Ouwerkerk W
    Clin Pharmacol Ther; 1985 Sep; 38(3):301-5. PubMed ID: 4028625
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The Combination of Scopolamine and Psychostimulants for the Prevention of Severe Motion Sickness.
    Zhang LL; Liu HQ; Yu XH; Zhang Y; Tian JS; Song XR; Han B; Liu AJ
    CNS Neurosci Ther; 2016 Aug; 22(8):715-22. PubMed ID: 27160425
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Comparison of treatment strategies for Space Motion Sickness.
    Davis JR; Jennings RT; Beck BG
    Acta Astronaut; 1993 Aug; 29(8):587-91. PubMed ID: 11541638
    [TBL] [Abstract][Full Text] [Related]  

  • 88. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action].
    Wang E
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct; 25(5):299-302, 319. PubMed ID: 2076342
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Dexamethasone mimicks the antimotion sickness effects of amphetamine and scopolamine.
    Kohl RL
    Acta Astronaut; 1986 Sep; 13(9):565-71. PubMed ID: 11538662
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Restricted sedation and absence of cognitive impairments after administration of intranasal scopolamine.
    Weerts AP; Pattyn N; Putcha L; Hoag SW; Van Ombergen A; Hallgren E; Van de Heyning PH; Wuyts FL
    J Psychopharmacol; 2015 Dec; 29(12):1231-5. PubMed ID: 26268532
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Prevention and treatment of motion sickness.
    Brainard A; Gresham C
    Am Fam Physician; 2014 Jul; 90(1):41-6. PubMed ID: 25077501
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Facilitation of adaptation and acute tolerance to stressful sensory input by doxepin and scopolamine plus amphetamine.
    Kohl RL; Sandoz GR; Reschke MF; Calkins DS; Richelson E
    J Clin Pharmacol; 1993 Nov; 33(11):1092-103. PubMed ID: 8300892
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Some otological problems during space flight.
    Johnson WH
    J Laryngol Otol; 1971 Dec; 85(12):1246-8. PubMed ID: 5316139
    [No Abstract]   [Full Text] [Related]  

  • 94. More on Transderm Scop patches.
    N Engl J Med; 1984 Nov; 311(21):1377-8. PubMed ID: 6493292
    [No Abstract]   [Full Text] [Related]  

  • 95. Transdermally administered scopolamine.
    Paasuke RT
    CMAJ; 1985 Nov; 133(10):956. PubMed ID: 4063911
    [No Abstract]   [Full Text] [Related]  

  • 96. Effects of ginger on motion sickness susceptibility and gastric function.
    Stewart JJ; Wood MJ; Wood CD; Mims ME
    Pharmacology; 1991; 42(2):111-20. PubMed ID: 2062873
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
    Patel PN; Ezzo DC
    Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time.
    Howland J; Rohsenow DJ; Minsky S; Snoberg J; Tagerud S; Hunt SK; Almeida A; Greece J; Allensworth-Davies D
    Int J Occup Environ Health; 2008; 14(4):250-6. PubMed ID: 19043911
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Motion sickness and its treatment (author's transl)].
    Petrin A
    Schweiz Rundsch Med Prax; 1974 Jan; 63(3):79-81. PubMed ID: 4153225
    [No Abstract]   [Full Text] [Related]  

  • 100. Transdermally administered scopolamine vs. dimenhydrinate. I. Effect on nausea and vertigo in experimentally induced motion sickness.
    Pyykkö I; Schalén L; Jäntti V
    Acta Otolaryngol; 1985; 99(5-6):588-96. PubMed ID: 4024909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.